Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy

NCT02420379 is registered in ClinicalTrials.gov with Sarepta Therapeutics, Inc. as lead sponsor.

NCT NCT02420379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02420379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
Lead sponsor
Sarepta Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
December 17, 2018
Enrollment
33 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy (dmd)